Table 2.

Association analysis between cubilin gene and megalin gene variants with type 2 diabetes and ESRD (additive, fully adjusted model)

GeneSNPMinor AlleleT2D-GENES Consortium Samples (Patients with T2D-ESRD Versus Healthy Controls)AXIOM Samples (Patients with T2D-ESRD Versus T2D Only and Healthy Controls)Meta-Analysis
N Patients/ControlsMAF Patients/ControlsP ValueOR95% CIN Patients/ControlsMAF Patients/ControlsP ValueOR95% CIP ValueOR95% CIDirection
LRP2rs17848169C512/5020.004/0.0120.010.190.05 to 0.681997/15790.005/0.010.020.540.32 to 0.900.0020.470.29 to 0.75− −
LRP2rs34291900T511/5010.003/0.0110.020.170.04 to 0.711997/15840.005/0.0060.180.670.38 to 1.200.030.560.33 to 0.95− −
LRP2rs4667591G511/5020.24/0.230.741.040.81 to 1.341991/15820.20/0.220.170.930.83 to 1.030.260.940.85 to 1.04 + −
LRP2rs144081819T512/5020.036/0.0330.631.150.65 to 2.011997/15840.036/0.0380.950.990.79 to 1.240.911.010.82 to 1.25+ −
LRP2rs143367996A512/5020.022/0.0320.301.410.74 to 2.701995/15840.023/0.0230.391.130.85 to 1.500.231.170.91 to 1.52+ +
LRP2rs61995913C512/5020.046/0.0470.590.870.53 to 1.431995/15820.043/0.0460.370.910.74 to 1.120.300.900.75 to 1.09− −
LRP2rs116456291T512/5020.036/0.0300.901.040.58 to 1.881993/15800.037/0.0370.811.030.82 to 1.290.791.030.83 to 1.27+ +
LRP2rs144864408T512/5020.001/0.0020.090.090.01 to 1.471997/15840.001/0.0010.740.730.12 to 4.480.230.390.09 to 1.80− −
CUBNrs1873469A512/5020.26/0.330.0030.720.58 to 0.901994/15810.28/0.290.660.980.89 to 1.070.120.930.86 to 1.02− −
CUBNrs144360241C512/5020.002/0.0010.0216.11.51 to 172.21998/15840.001/0.0020.880.920.28 to 2.970.311.610.56 to 4.64+ −
CUBNrs148100631C512/5020.001/0.0050.040.070.01 to 0.881997/15830.001/0.0010.631.480.29 to 7.480.470.600.16 to 2.34− +
CUBNrs1801239C512/5020.029/0.0290.951.020.55 to 1.911993/15820.031/0.0240.021.371.06 to 1.780.031.311.03 to 1.67+ +
CUBNrs74431427A512/5020.023/0.0180.641.180.59 to 2.331989/15810.020/0.0190.881.020.76 to 1.380.751.050.80 to 1.38+ +
CUBNrs111265129C512/5020.038/0.0410.950.980.58 to 1.661996/15790.043/0.0410.461.080.88 to 1.340.511.070.88 to 1.30− +
CUBNrs780807A511/5020.31/0.290.521.080.86 to 1.351988/15820.30/0.300.701.020.93 to 1.120.551.030.94 to 1.12+ +
CUBNrs2271460C512/5020.016/0.0150.411.430.61 to 3.341993/15780.01/0.0070.371.240.78 to 1.960.241.280.85 to 1.92+ +
CUBNrs2271462T512/5020.14/0.130.631.080.80 to 1.441991/15800.14/0.140.901.010.89 to 1.140.761.020.91 to 1.14+ +
CUBNrs12259370T512/5020.071/0.0610.421.190.78 to 1.831955/15440.068/0.0670.721.030.87 to 1.220.531.050.90 to 1.23+ +
  • Sample sizes may be smaller than those displayed in Table 1 because of missing apolipoprotein L1 genotypes. Direction reflects effect in T2D-GENES and AXIOM, respectfully. SNP, single-nucleotide polymorphism; T2D-GENES Consortium, Type 2 Diabetes Genes Consortium; T2D, type 2 diabetes; AXIOM, Affymetrix Axiom Biobank Genotyping Array; MAF, minor allele frequency; OR, odds ratio; 95% CI, 95% confidence interval; LRP2, megalin; CUBN, cubilin.